FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366991839> ?p ?o ?g. }

• W4366991839 abstract "<div>AbstractPurpose:<p>AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC.</p>Experimental Design:<p>Patients with mCRC unselected for MMR status were randomly assigned (1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). qRT-PCR by DetermaIO was performed on RNA purified from pretreatment tumors of 132 (61%) of 218 enrolled patients. A binary result (IO^pos vs. IO^neg) adopting the preestablished DetermaIO cut-off point (0.09) was obtained, and an exploratory optimized cut-off point (IO^OPT) was computed in the overall population and in pMMR subgroup (IO^OPTpos vs. IO^OPTneg).</p>Results:<p>DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumors were IO^pos. IO^pos tumors achieved higher PFS benefit from atezolizumab arm than IO^neg (HR: 0.39 vs. 0.83; <i>P</i>_interaction = 0.066). In pMMR tumors (<i>N</i> = 110), a similar trend was observed (HR: 0.47 vs. 0.93; <i>P</i>_interaction = 0.139). In the overall population, with the computed IO^OPT cut-off point (0.277), 16 (13%) tumors were IO^OPTpos and they derived higher PFS benefit from atezolizumab than IO^OPTneg (HR: 0.10 vs. 0.85, <i>P</i>_interaction = 0.004). Similar results were found in the pMMR subgroup.</p>Conclusions:<p>DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IO^OPT cut-off point should be validated in independent mCRC cohorts.</p></div>" @default.
• W4366991839 created "2023-04-27" @default.
• W4366991839 creator A5004626743 @default.
• W4366991839 creator A5008822450 @default.
• W4366991839 creator A5010230522 @default.
• W4366991839 creator A5016264665 @default.
• W4366991839 creator A5017086518 @default.
• W4366991839 creator A5019332793 @default.
• W4366991839 creator A5026748433 @default.
• W4366991839 creator A5028325185 @default.
• W4366991839 creator A5033032136 @default.
• W4366991839 creator A5033135467 @default.
• W4366991839 creator A5043534813 @default.
• W4366991839 creator A5050750573 @default.
• W4366991839 creator A5056137510 @default.
• W4366991839 creator A5057209749 @default.
• W4366991839 creator A5057503389 @default.
• W4366991839 creator A5064495942 @default.
• W4366991839 creator A5070615133 @default.
• W4366991839 creator A5072473792 @default.
• W4366991839 creator A5072503801 @default.
• W4366991839 creator A5074681974 @default.
• W4366991839 creator A5079437223 @default.
• W4366991839 creator A5080776095 @default.
• W4366991839 creator A5081985776 @default.
• W4366991839 creator A5085745169 @default.
• W4366991839 creator A5087670194 @default.
• W4366991839 date "2023-06-13" @default.
• W4366991839 modified "2023-10-16" @default.
• W4366991839 title "Data from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer" @default.
• W4366991839 doi "https://doi.org/10.1158/1078-0432.c.6615933" @default.
• W4366991839 hasPublicationYear "2023" @default.
• W4366991839 type Work @default.
• W4366991839 citedByCount "0" @default.
• W4366991839 crossrefType "posted-content" @default.
• W4366991839 hasAuthorship W4366991839A5004626743 @default.
• W4366991839 hasAuthorship W4366991839A5008822450 @default.
• W4366991839 hasAuthorship W4366991839A5010230522 @default.
• W4366991839 hasAuthorship W4366991839A5016264665 @default.
• W4366991839 hasAuthorship W4366991839A5017086518 @default.
• W4366991839 hasAuthorship W4366991839A5019332793 @default.
• W4366991839 hasAuthorship W4366991839A5026748433 @default.
• W4366991839 hasAuthorship W4366991839A5028325185 @default.
• W4366991839 hasAuthorship W4366991839A5033032136 @default.
• W4366991839 hasAuthorship W4366991839A5033135467 @default.
• W4366991839 hasAuthorship W4366991839A5043534813 @default.
• W4366991839 hasAuthorship W4366991839A5050750573 @default.
• W4366991839 hasAuthorship W4366991839A5056137510 @default.
• W4366991839 hasAuthorship W4366991839A5057209749 @default.
• W4366991839 hasAuthorship W4366991839A5057503389 @default.
• W4366991839 hasAuthorship W4366991839A5064495942 @default.
• W4366991839 hasAuthorship W4366991839A5070615133 @default.
• W4366991839 hasAuthorship W4366991839A5072473792 @default.
• W4366991839 hasAuthorship W4366991839A5072503801 @default.
• W4366991839 hasAuthorship W4366991839A5074681974 @default.
• W4366991839 hasAuthorship W4366991839A5079437223 @default.
• W4366991839 hasAuthorship W4366991839A5080776095 @default.
• W4366991839 hasAuthorship W4366991839A5081985776 @default.
• W4366991839 hasAuthorship W4366991839A5085745169 @default.
• W4366991839 hasAuthorship W4366991839A5087670194 @default.
• W4366991839 hasConcept C121608353 @default.
• W4366991839 hasConcept C126322002 @default.
• W4366991839 hasConcept C143998085 @default.
• W4366991839 hasConcept C2775949291 @default.
• W4366991839 hasConcept C2776694085 @default.
• W4366991839 hasConcept C2777701055 @default.
• W4366991839 hasConcept C2777802072 @default.
• W4366991839 hasConcept C2780057760 @default.
• W4366991839 hasConcept C2780259306 @default.
• W4366991839 hasConcept C2780962732 @default.
• W4366991839 hasConcept C2908647359 @default.
• W4366991839 hasConcept C526805850 @default.
• W4366991839 hasConcept C71924100 @default.
• W4366991839 hasConcept C99454951 @default.
• W4366991839 hasConceptScore W4366991839C121608353 @default.
• W4366991839 hasConceptScore W4366991839C126322002 @default.
• W4366991839 hasConceptScore W4366991839C143998085 @default.
• W4366991839 hasConceptScore W4366991839C2775949291 @default.
• W4366991839 hasConceptScore W4366991839C2776694085 @default.
• W4366991839 hasConceptScore W4366991839C2777701055 @default.
• W4366991839 hasConceptScore W4366991839C2777802072 @default.
• W4366991839 hasConceptScore W4366991839C2780057760 @default.
• W4366991839 hasConceptScore W4366991839C2780259306 @default.
• W4366991839 hasConceptScore W4366991839C2780962732 @default.
• W4366991839 hasConceptScore W4366991839C2908647359 @default.
• W4366991839 hasConceptScore W4366991839C526805850 @default.
• W4366991839 hasConceptScore W4366991839C71924100 @default.
• W4366991839 hasConceptScore W4366991839C99454951 @default.
• W4366991839 hasLocation W43669918391 @default.
• W4366991839 hasOpenAccess W4366991839 @default.
• W4366991839 hasPrimaryLocation W43669918391 @default.
• W4366991839 hasRelatedWork W2010928484 @default.
• W4366991839 hasRelatedWork W2050348440 @default.
• W4366991839 hasRelatedWork W2051540233 @default.
• W4366991839 hasRelatedWork W2058385450 @default.
• W4366991839 hasRelatedWork W2066462266 @default.
• W4366991839 hasRelatedWork W2073256875 @default.
• W4366991839 hasRelatedWork W2141311805 @default.
• W4366991839 hasRelatedWork W2340695374 @default.
• W4366991839 hasRelatedWork W2617055067 @default.

• next